Yiwei Liu

Email

Start Year

2021

Developing antibody therapeutics for T cell-acute lymphoblastic leukemia (T-ALL)

Despite successes in developing effective immunotherapy for B-ALL, little progress has been made for T-ALL. New targets which distinguish T-ALL blasts and normal T lymphocytes need to be identified and novel immunotherapy agents developed for this type of ALL.

My previous work includes high molecular weight polyethylene glycol (PEG) and anti-PEG antibodies in hypersensitivity reactions to pegaspargase, liposome-conjugated PEG, and unconjugated PEG; pegaspargase pharmacokinetics; age-dependent hepatotoxicity of pegaspargase; pharmacogenomics of chemotherapy-induced toxicity in pediatric leukemia.

Publications

Liu Y, Smith CA, Panetta JC, Yang W, Thompson LE, Counts JP, Molinelli AR, Pei D, Kornegay NM, Crews KR, Swanson H, Cheng C, Karol SE, Evans WE, Inaba H, Pui CH, Jeha S, Relling MV. Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. J Clin Oncol. 2019 Aug 10;37(23):2051-2061. doi: 10.1200/JCO.18.02439. Epub 2019 Jun 12. PMCID: PMC6804844.

Liu Y, Panetta JC, Yang W, Karol SE, Cheng C, Yang JJ, Evans WE, Inaba H, Pui CH, Jeha S, Relling MV. Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment. Blood. 2020 Dec 17;136(25):2955-2958. doi: 10.1182/blood.2020006214. PMCID: PMC7751363.

Stone CA Jr, Liu Y, Relling MV, Krantz MS, Pratt AL, Abreo A, Hemler JA, Phillips EJ. Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1533-1540.e8. doi: 10.1016/j.jaip.2018.12.003. Epub 2018 Dec 14. PMCID: PMC6706272.